| # | Drug | Count |
|---|---|---|
| 0 | ETOPOSIDE | 74 |
| 1 | CYCLOPHOSPHAMIDE | 69 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 69 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 69 |
| 4 | CISPLATIN | 67 |
| 5 | METHOTREXATE SODIUM | 61 |
| 6 | DOXORUBICIN | 55 |
| 7 | METHOTREXATE | 53 |
| 8 | IFOSFAMIDE | 48 |
| 9 | IFOSFAMIDE FOR INJECTION | 48 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DEXRAZOXANE FOR INJECTION | 12 | 0.0127 |
| 1 | POTASSIUM PHOSPHATE, MONOBASIC AND SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | 1 | 0.0055 |
| 2 | THIOTEPA | 28 | 0.0029 |
| 3 | DACTINOMYCIN | 5 | 0.0023 |
| 4 | IFOSFAMIDE FOR INJECTION | 48 | 0.0022 |
| 5 | TALIGLUCERASE ALFA | 1 | 0.0017 |
| 6 | PEXIDARTINIB HYDROCHLORIDE | 1 | 0.0014 |
| 7 | DINUTUXIMAB | 1 | 0.0012 |
| 8 | INFLIXIMAB-DYYB | 4 | 0.0012 |
| 9 | LAROTRECTINIB | 1 | 0.0011 |
| # | Drug class | Count |
|---|---|---|
| 0 | Alkylating Drug [EPC] | 99 |
| 1 | Platinum-based Drug [EPC] | 79 |
| 2 | Topoisomerase Inhibitor [EPC] | 76 |
| 3 | Folate Analog Metabolic Inhibitor [EPC] | 53 |
| 4 | Corticosteroid [EPC] | 30 |
| 5 | Parathyroid Hormone Analog [EPC] | 26 |
| 6 | RANK Ligand Inhibitor [EPC] | 26 |
| 7 | Kinase Inhibitor [EPC] | 19 |
| 8 | Tumor Necrosis Factor Blocker [EPC] | 19 |
| 9 | Microtubule Inhibitor [EPC] | 13 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Actinomycin [EPC] | 5 | 0.0023 |
| 1 | Topoisomerase Inhibitor [EPC] | 76 | 0.0010 |
| 2 | Glycolipid Disialoganglioside-directed Antibody [EPC] | 1 | 0.0009 |
| 3 | Lymphocyte Growth Factor [EPC] | 1 | 0.0008 |
| 4 | Recombinant Human Growth Hormone [EPC] | 13 | 0.0006 |
| 5 | Alkylating Drug [EPC] | 99 | 0.0004 |
| 6 | Oxytocic [EPC] | 1 | 0.0003 |
| 7 | Platinum-based Drug [EPC] | 79 | 0.0003 |
| 8 | Parathyroid Hormone Analog [EPC] | 26 | 0.0002 |
| 9 | Progestin Antagonist [EPC] | 1 | 0.0002 |